A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
This is a phase 1/1b open-label, multicentre, dose-selection study of CPI-444, an oral small
molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune
system. This trial will study the safety, tolerability, and anti-tumour activity of CPI-444
as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various
solid tumours. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine
suppresses the anti-tumour activity of T cells and other immune cells.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society